Author:
Kananen L.,Hurme M.,Jylhä M.,Härkänen T.,Koskinen S.,Stenholm S.,Kähönen M.,Lehtimäki T.,Ukkola O.,Jylhävä J.
Abstract
AbstractIncreased levels of circulating cell-free DNA (cf-DNA) are associated with and predict poor health outcomes. However, its predictive ability for mortality in population-based samples remains understudied. We analysed the capability of cf-DNA to predict all-cause mortality and assessed whether it adds predictive value on top of the other risk factors in the Health 2000 survey (n = 1,257, 46–76 years of age, 15-years-follow-up, 18% deceased). When analysed in a multivariate model with the other factors that independently predicted mortality in the sample (age, gender, self-rated health, smoking and plasma levels of glucose and adiponectin), increases in cf-DNA levels were associated with increased risk of mortality (hazard ratio [HR] for 0.1 µg increase in cf-DNA: 1.017, 95% confidence interval [CI] 1.008–1.026, p = 0.0003). Inclusion of cf-DNA in the model improved the model fit and discrimination. Stratifying the analysis by cardiovascular disease (CVD) status indicated that cf-DNA predicted mortality equally well in individuals with (HR 1.018, 95% CI 1.008–1.026, p = 0.002) and without (HR 1.018, 95% CI 1.001–1.035, p = 0.033) CVD. In conclusion, our study indicates that cf-DNA level predicts mortality in middle-aged and older individuals, also among those with established CVD, and adds significant value to mortality prediction. Our results thus underscore the role of cf-DNA as a viable marker of health.
Funder
Emil Aaltosen Säätiö
Yrjö Jahnssonin Säätiö
Academy of Finland
Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospitals
Finnish Foundation for Cardiovascular Research
Tampere Tuberculosis Foundation
Signe and Ane Gyllenberg Foundation
Diabetes Research Foundation of Finnish Diabetes Association
EU Horizon 2020
Tampere University Hospital Supporting Foundation
Swedish Research Council
Strategic Research Program in Epidemiology at Karolinska Institutet
Loo and Hans Osterman Foundation
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Song, H., Nan, Y. & Cheng, X. W. Circulating cf-DNA: a promising, noninvasive tool for assessment of early cardio-metabolic risk. Atherosclerosis 233, 307–309 (2014).
2. Gogenur, M., Burcharth, J. & Gogenur, I. The role of total cell-free DNA in predicting outcomes among trauma patients in the intensive care unit: a systematic review. Crit. Care 21, 14-016-1578-9. eCollection 2017 (2017).
3. Rannikko, J. et al. Plasma cell-free DNA and qSOFA score predict 7-day mortality in 481 emergency department bacteraemia patients. J. Intern. Med. 284, 418–426 (2018).
4. Zeerleder, S. et al. Elevated nucleosome levels in systemic inflammation and sepsis. Crit. Care Med. 31, 1947–1951 (2003).
5. Arafat, E. et al. Circulating cell-free DNA as a sensitive biomarker in patients with acute myocardial infarction. Menoufia Med. J. 31, 772–779 (2018).
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献